1. At a Glance
If Indian pharma stocks were Bollywood characters, Zota Health Care Limited would be the over-ambitious entrepreneur who opened 2,331 stores, raised ₹350 crore from institutions, doubled quarterly revenue, and still somehow managed to lose money doing it.
Market cap stands at ₹4,403 crore, the stock is hovering around ₹1,304, and in the last three months it has politely reminded investors that gravity exists (-13.5%). Over one year, however, it is up 33.4%, which tells you speculation is alive and well.
The latest Q3 FY26 results show ₹143 crore in revenue, a sharp 98.2% YoY jump, but PAT of -₹29.5 crore and an EPS of -₹8.73. ROE is a spicy -36%, ROCE is -17%, and the stock trades at ~14x book value despite bleeding cash.
So yes, revenue is sprinting. Profitability? Still stuck tying its shoelaces.
2. Introduction – The Zota Paradox
Zota Health Care is a fascinating contradiction. On one side, it is building India’s largest generic pharmacy network under the Davaindia brand, preaching affordable healthcare and private-label efficiency. On the other side, its financials look like a diet plan that promises abs but delivers only hunger.
The company operates across domestic pharma distribution, retail generic pharmacies, and exports to 30+ countries. It manufactures in a WHO-GMP facility in Surat SEZ and boasts hundreds of dossiers filed globally. On paper, this should scream “scalable pharma platform.”
Yet, despite 30%+ sales CAGR over 3 years, Zota’s profits have gone AWOL. FY25 ended with ₹72.7 crore loss, margins collapsed, interest costs climbed, and depreciation exploded thanks to aggressive expansion.
The big question: is Zota in a temporary investment phase… or permanently addicted to growth without profits?
3. Business Model – WTF Do They Even Do?
Zota runs three engines, all revving loudly:
1) Domestic Distribution
The OG business. Generic drugs, OTC products, 1,050+ distributors, and over 3,000 products. This is
